ID   KU-19-20
AC   CVCL_5213
SY   KU 19-20; KU19-20; Keio University-19-20
DR   cancercelllines; CVCL_5213
DR   GEO; GSM374461
DR   Progenetix; CVCL_5213
DR   Wikidata; Q54900671
RX   PubMed=10496353;
RX   PubMed=10994781;
WW   Info; COPE; -; http://www.cells-talk.com/index.php/page/copelibrary?key=KU-19-20
CC   Population: Japanese.
CC   Doubling time: 58.7 hours (Note=At 50th passage) (PubMed=10994781).
CC   Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
DI   NCIt; C9385; Renal cell carcinoma
DI   ORDO; Orphanet_217071; Renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   67Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 15
//
RX   PubMed=10496353; DOI=10.1038/sj.bjc.6690688; PMCID=PMC2362876;
RA   Sumitomo M., Tachibana M., Murai M., Hayakawa M., Nakamura H.,
RA   Takayanagi A., Shimizu N.;
RT   "Overexpression of IL-1ra gene up-regulates interleukin-1beta
RT   converting enzyme (ICE) gene expression: possible mechanism underlying
RT   IL-1beta-resistance of cancer cells.";
RL   Br. J. Cancer 81:277-286(1999).
//
RX   PubMed=10994781; DOI=10.1007/s004410000235;
RA   Tachibana M., Miyakawa A., Nakashima J., Murai M., Nakamura K.,
RA   Kubo A., Hata J.-i.;
RT   "Autocrine growth promotion by multiple hematopoietic growth factors
RT   in the established renal cell carcinoma line KU-19-20.";
RL   Cell Tissue Res. 301:353-367(2000).
//